Disclosure - Responsible Transparency
Within the framework of European level efforts to increase transparency, responsibility and credibility in the pharmaceutical industry, the pharmaceutical companies-members of KEFEA and EFPIA have taken the decision to disclose payments and other transfers of value to healthcare professionals (HCPs) and healthcare organisations (HCOs).
The public disclosure of transfers of value marks a significant development in the relationship between industry and HCPs. The first time these transfers of value have been made public across Europe was in 2016 and the industry is committed to working with all stakeholders in healthcare to ensure that the value of these relationships and the benefits of greater transparency are understood. KEFEA’ s Code of Conduct contains all relevant provisions.
What kind of information is disclosed?
The disclosed information concerns, among others, grants to scientific organisations, consultancy fees for speeches, and payment of costs for healthcare professionals to attend medical conferences in Cyprus and abroad. They also include the cost of registration, accommodation and travel to conference venues.
How is the data disclosed?
Disclosure is made either by name with the written consent of the affected party or on aggregate and anonymously if consent has not been given by the HCP.
When did the transfers of value take place?
The transfers of value disclosed below where made in 2015 and 2016.
Where is this information available?
KEFEA’s website hosts web links to each company’s disclosure platform.
Which companies are obliged to follow the Code?
Adherence to the Code is obligatory for all members of KEFEA, as well as all members of the European Federation of Pharmaceutical Industries and Associations (EFPIA) who are active in Cyprus.
What do we want to achieve with this initiative?
Our aim is to strengthen the legitimate relationship between pharmaceutical companies and healthcare professionals and healthcare organisations by making these relationships more transparent and therefore better understood by patients and other stakeholders.